Vistagen initiates fasedienol repeat dose study for the acute treatment of social anxiety disorder

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in phase 3 development for the acute treatment of social anxiety disorder (sad). the repeat dose study is a small exploratory u.s. phase 2 multi-center, randomized, double-blind, place.
VTGN Ratings Summary
VTGN Quant Ranking